Sarcoma Trials at MSK

Researchers want to find the best dose of avutometinib to treat children and young adults with advanced solid tumors. The people in this study have cancers that have spread or come back after treatment. In addition, their cancers have a mutation (change or variant) in a protein family called MAPK. These proteins tell cancer cells to grow.

Researchers want to find the best dose of CRD3874-SI to use in people with sarcoma or Merkel cell carcinoma (MCC). The people in this study have sarcoma or MCC that has spread. CRD3874-SI attaches to a type of protein called a STING. This protein encourages immune cells to kill cancer cells, which may slow or stop cancer growth. CRD3874-SI is given intravenously (by vein).

Researchers want to find the best dose of DCC-3009 to use in people with gastrointestinal stromal tumors (GIST). The people in this study have GIST that has metastasized (spread) after treatment. In addition, their cancers have a mutation (change) in the KIT or PDGFRA gene. These mutations are common in people with GIST and can cause cancer to grow.

Researchers want to find the best dose of DS-2243a to use in people with solid tumors. The people in this study have these solid tumors, which have spread beyond their original location:

In this study, researchers want to see how safe IDRX-42 is and how well it works to treat cancer. The people in this study have gastrointestinal stromal tumor (GIST) that keeps growing after treatment. In addition, their cancer has metastasized (spread) or is inoperable (cannot be taken out with surgery).

Researchers are seeking the best dose of mRNA-4203 to give with a cellular therapy in people with melanoma or sarcoma. The cellular therapy is called IMA203 and is custom-made from each patient's white blood cells.

In this study, researchers are assessing the safety of the drug lurbinectedin in young people with solid tumors. In the first part, they will find the highest dose of lurbinectedin to use safely in children with solid tumors. If your child joins, this is the part of the study they will be in.

In this study, researchers are finding the highest dose of MQ710 to use safely in people with certain types of advanced cancer. The people in this study have solid tumors that came back or grew even after treatment. In a later part of the study, the researchers will assess MQ710 plus another drug called pembrolizumab.

Researchers are evaluating PYX-201 in people with solid tumors that have spread and keep growing after treatment. The people in this study have these cancers:

Researchers want to find the best dose of TORL-1-23 to use in people with advanced solid tumors. The people in this study have solid tumors that have spread and cannot be successfully treated with standard therapies.